Genome Engineering Market is estimated to be US$ 29.7 billion by 2032 with a CAGR of 15.7% during the forecast period 2032

Genome engineering is a method that allows scientists to alter the DNA of many organisms, including plants, bacteria, and animals. Genome editing, also called gene editing, is a group of technologies that enable researchers to alter an organism's DNA. Genome editing, especially the use of CRISPR-Cas9-based methods, is revolutionizing biology through its impact on research and their translation into applications in biomedicine. This technology makes it possible to add, remove, or modify genetic material at specific locations in the genome.Genome Engineering Market accounted for US$ 6.9 billion in 2022 and is estimated to be US$ 29.7 billion by 2032 and is anticipated to register a CAGR of 15.7%

The report “Genome Engineering Market, By Technology (CRISPR, TALEN, ZFN, and Others), By Application (Cell line Engineering and Genetic Engineering), By End-User (Pharmaceutical and Biotechnology Companies, Academic and Research Institutes, and Contract Research Organizations),  and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Trends, Analysis and Forecast till 2032”

 

Key Highlights:

• In October 2022, Vor Bio, a clinical-stage cell and genome engineering company, announced in October data demonstrating the ability of the company's new platform to use a variety of base editing strategies to successfully delete multiple cell surface targets from hematopoietic stem cells (HSCs), potentially enabling next-generation transplants for the treatment of acute myeloid leukemia (AML).
• In October 2019, Synthego launched Genome Engineering Services for Induced Pluripotent Stem Cells, an extension of automated cell editing capabilities designed to achieve extremely high editing efficiency of iPS cells on an industrial scale, and to meet the long-term challenge of research and drug development needed for translational medicine with the high- The death of quality, physiologically relevant biological models.

Analyst View:

Genome editing is of great interest in the prevention and treatment of human disease, currently, genome editing is used in laboratory cells and animal models to understand disease. While scientists are still working to determine whether this approach is safe and effective for use in people, increasing strategic collaboration for genome engineering technology by key players is expected to fuel market growth over the forecast period.

 Browse 60 market data tables* and 35 figures* through 140 slides and in-depth TOC on “Genome Engineering Market, By Technology (CRISPR, TALEN, ZFN, and Others), By Application (Cell line Engineering and Genetic Engineering), By End-User (Pharmaceutical and Biotechnology Companies, Academic and Research Institutes, and Contract Research Organizations), and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Trends, Analysis and Forecast till 2032”

Key Market Insights from the report:

Genome Engineering Market accounted for US$ 6.9 billion in 2022 and is estimated to be US$ 29.7 billion by 2032 and is anticipated to register a CAGR of 15.7%. The Genome Engineering Market is segmented based on Technology, Application, End User and Region.

• Based on Technology, Genome Engineering Market is segmented into CRISPR, TALEN, ZFN, and Others.
• Based on Application, Genome Engineering Market is segmented into Cell line Engineering and Genetic Engineering.
• Based on End User, Genome Engineering Market is segmented into Pharmaceutical and Biotechnology Companies, Academic and Research Institutes, and Contract Research Organizations.
• By Region, the Genome Engineering Market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

Competitive Landscape & their strategies of Genome Engineering Market:

The prominent players operating in the Genome Engineering Market includes, Thermo Fisher Scientific Inc., CRISPR Therapeutics AG, Intellia Therapeutics, Inc., Editas Medicine, Inc., Sangamo Therapeutics, Inc., Bluebird Bio, Inc., Cellectis S.A., Merck Group, and Vigene Biosciences, Transposagen Biopharmaceuticals.

The market provides detailed information regarding the industrial base, productivity, strengths, manufacturers, and recent trends which will help companies enlarge the businesses and promote financial growth. Furthermore, the report exhibits dynamic factors including segments, sub-segments, regional marketplaces, competition, dominant key players, and market forecasts. In addition, the market includes recent collaborations, mergers, acquisitions, and partnerships along with regulatory frameworks across different regions impacting the market trajectory. Recent technological advances and innovations influencing the global market are included in the report.

About Prophecy Market Insights

Prophecy Market Insights is specialized market research, analytics, marketing/business strategy, and solutions that offers strategic and tactical support to clients for making well-informed business decisions and to identify and achieve high-value opportunities in the target business area. We also help our clients to address business challenges and provide the best possible solutions to overcome them and transform their business.

To know more

Contact Us:

Sales

Prophecy Market Insights

U.S: 1 860 531 2574

RoW: 91 7775049802

Email- [email protected]

Website- www.prophecymarketinsights.com

Blog- www.prophecyjournals.com